• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Hepion Pharmaceuticals Inc.

    1/24/25 8:32:30 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HEPA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Hepion Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, $.0001 par value

    (Title of Class of Securities)


    426897302

    (CUSIP Number)


    01/21/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    426897302


    1Names of Reporting Persons

    BIGGER CAPITAL FUND L P
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,060,883.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,060,883.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,060,883.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    426897302


    1Names of Reporting Persons

    Bigger Capital Fund GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,060,883.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,060,883.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,060,883.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    426897302


    1Names of Reporting Persons

    Bigger Michael
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,060,883.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,060,883.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,060,883.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Hepion Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    399 Thornall Street, First Floor, Edison, NJ 08837
    Item 2. 
    (a)Name of person filing:

    Bigger Capital Fund, LP ("Bigger Capital") Bigger Capital Fund GP, LLC ("Bigger GP") Michael Bigger Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    Bigger Capital Fund, LP 2250 Red Springs Drive Las Vegas, NV 89135 Bigger Capital Fund GP, LLC 2250 Red Springs Drive Las Vegas, NV 89135 Michael Bigger 2250 Red Springs Drive Las Vegas, NV 89135
    (c)Citizenship:

    Bigger Capital Fund, LP Citizenship: Delaware Bigger Capital Fund GP, LLC Citizenship: Delaware Michael Bigger Citizenship: United States
    (d)Title of class of securities:

    Common Stock, $.0001 par value
    (e)CUSIP No.:

    426897302
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of January 23, 2025, Bigger Capital beneficially owned 1,060,883 shares of Common Stock which includes shares of the Issuer's Common Stock issuable upon the exercise of Pre-Funded Warrants the exercise of which is subject to a 9.99% beneficial ownership limitation. The amounts do not include 994,958 shares and 994,958 shares issuable upon the exercise of Series A Warrants and Series B Warrants, respectively, the exercise of which are subject to shareholder approval and a 4.99% beneficiary ownership limitation. The percentage set forth on Row (11) of the cover page for the reporting person is based on 10,619,458 shares of Common Stock outstanding after the offering described in the Issuer's Prospectus filed under Rule 424(b)(4) with the Securities and Exchange Commission on January 23, 2025. Bigger GP, as the general partner of Bigger Capital, may be deemed to beneficially own the Issuer's securities described herein. Mr. Bigger, as the managing member of Bigger GP may be deemed to beneficially own the Issuer's securities described herein. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Each of Bigger GP and Mr. Bigger disclaims beneficial ownership of the shares of Common Stock beneficially owned by Bigger Capital. The filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities. Regarding Item 5 below, subsequent to January 23, 2025, the Reporting Person sold 1,060,883 shares of Common Stock and accordingly, the Reporting Person as of January 24, 2025 does not own any securities of the Issuer (other than shares of Common Stock issuable upon exercise of Series A and Series B Warrants, the exercise of which are subject to shareholder approval and a 4.99% beneficial ownership limitation) and will not be amending this Schedule 13G.
    (b)Percent of class:

    As of the close of business on January 23, 2025, each of Bigger Capital, Bigger GP, and Mr. Bigger may be deemed to beneficially own approximately 9.99% of the outstanding shares of Common Stock. Subsequent to January 23, 2025, each of Bigger Capital, Bigger GP and Mr. Bigger had no beneficial ownership due to the sale of 10,619,458 shares of Common Stock and the requirement in the Series A and Series B warrants that the exercise of such securities is subject to stockholder approval.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit 99.1.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BIGGER CAPITAL FUND L P
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member of Bigger Capital Fund GP, LLC, its general partner
    Date:01/24/2025
     
    Bigger Capital Fund GP, LLC
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member
    Date:01/24/2025
     
    Bigger Michael
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger
    Date:01/24/2025
    Exhibit Information

    99.1 - Joint Filing Agreement

    Get the next $HEPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HEPA

    DatePrice TargetRatingAnalyst
    2/28/2022$3.50Overweight
    Cantor Fitzgerald
    More analyst ratings

    $HEPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Purcell Michael J.

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    3/7/24 4:15:14 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Purcell Michael J.

    3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    3/6/24 4:30:41 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Jacob Gary S

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    2/21/24 8:01:44 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

    MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company's common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA. About Hepion Pharmaceuticals Hepion is a clinical stage biopharmaceutical company that is developing and commercializing diagnost

    6/25/25 8:30:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

    MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that Dr. Kaouthar Lbiati has been named as interim Chief Executive Officer, effective June 16, 2025. Dr. Lbiati is replacing John Brancaccio, who is retiring for personal reasons. Dr. Lbiati's appointment signals a new chapter for Hepion—one focused on strategic renewal, value creation, and diagnostic innovation in areas of significant unmet clin

    6/16/25 8:30:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

    MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori and HCC, today announced that on May 9, 2025, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shar

    5/12/25 4:30:00 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    SEC Filings

    View All

    SEC Form 8-K filed by Hepion Pharmaceuticals Inc.

    8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

    1/15/26 4:15:53 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Hepion Pharmaceuticals Inc.

    10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

    11/12/25 2:44:42 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Hepion Pharmaceuticals Inc.

    SCHEDULE 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

    8/14/25 9:41:01 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wijngaard Peter bought $15,350 worth of shares (5,000 units at $3.07), increasing direct ownership by 111% to 9,501 units (SEC Form 4)

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    11/28/23 6:55:05 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Wijngaard Peter bought $16,841 worth of shares (3,000 units at $5.61), increasing direct ownership by 200% to 4,501 units

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    9/20/23 11:27:22 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Foster Robert T bought $8,960 worth of shares (1,600 units at $5.60), increasing direct ownership by 3% to 50,470 units

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    9/19/23 9:01:30 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Hepion Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of Hepion Pharmaceuticals with a rating of Overweight and set a new price target of $3.50

    2/28/22 8:01:07 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Financials

    Live finance-specific insights

    View All

    Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

    - Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - "These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat's novel mechanism of action represents a fresh approach to the treatment of severe liver disease." (Patrick Mayo, PhD, Hepion's Senior VP, Clinical Pharmacology & Analytics) EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the t

    11/13/23 4:05:00 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat

    EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it expects to release additional efficacy data from the Phase 2 ALTITUDE-NASH clinical trial of its lead drug, rencofilstat, after market close on Monday, November 13, 2023. The data release will follow a late-breaker poster presentation by Hepion's Senior Vice President, Clinical Pharmacology, Patrick Mayo, PhD, at the

    11/10/23 8:50:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

    - Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH' paired biopsy trial - EDISON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence ("AI")-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced positive topline results from its recentl

    5/22/23 7:00:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Leadership Updates

    Live Leadership Updates

    View All

    Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

    EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company's Board of Directors, effective March 5, 2024. Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a consultant from 2015 to 2017 and an Audit Partner from 1979 until 2015. Mr. Purcell also currently serves as a financial advisor to several emerging growth companies. Mr. Purcell is a certified p

    3/6/24 8:30:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theralase(R) Announces Appointment of New Independent Director

    TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc. Dr. Lbiati received her Doctor of Medicine from Rabat, Morocco's Mohammed V University and a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a premier European cancer center and one o

    6/6/23 7:00:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

    EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), today announced the appointments of Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its Board of Directors, effective immediately. "We are thrilled to welcome individuals of this caliber to our Board," said Hepion's Chairman, Gary S. Jacob, Ph.D. "Mr. Reddi and Dr. Lbiati have a remarkable wealth of experience across all aspects of drug development, from clinical research to med

    6/28/22 8:30:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc.

    SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

    11/14/24 4:07:59 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Hepion Pharmaceuticals Inc.

    SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

    2/14/24 3:38:57 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

    2/14/22 6:05:01 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care